Literature DB >> 16305309

Assessing the minimum number of data points required for accurate IC50 determination.

Robert J Turner1, Steven J Charlton.   

Abstract

Combinatorial chemistry technology has enabled the synthesis of large, targeted libraries consisting of a much higher ratio of pharmacologically active compounds than traditional compound archives. This has resulted in a higher number of compounds requiring follow-up characterisation in full 50% inhibitory concentration (IC50) curves after the preliminary screen. The aim of this study was to develop a new assay format and analysis protocol for IC50 determination from the minimum number of data points so that more information could be derived from a primary inhibition screen. Data points from existing 10-point IC50 curves were used retrospectively to test the accuracy of IC50 predictions derived from just one or two compound concentrations. Regression analysis showed that both methods were useful, although, as expected, two compound concentrations gave more accurate IC50 predictions. A final experimental data set comparing IC50 values derived from a two- and 10- point assay format gave highly comparable data (r2 = 0.89). This study shows that it is possible to generate IC50 values from an appropriately designed primary inhibition screen using two compound concentrations, reducing the requirement for follow-up IC50 determinations.

Mesh:

Year:  2005        PMID: 16305309     DOI: 10.1089/adt.2005.3.525

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  9 in total

1.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Authors:  James Inglese; Douglas S Auld; Ajit Jadhav; Ronald L Johnson; Anton Simeonov; Adam Yasgar; Wei Zheng; Christopher P Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

2.  Compound Management for Quantitative High-Throughput Screening.

Authors:  Adam Yasgar; Paul Shinn; Ajit Jadhav; Douglas Auld; Sam Michael; Wei Zheng; Christopher P Austin; James Inglese; Anton Simeonov
Journal:  JALA Charlottesv Va       Date:  2008-04

3.  Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases.

Authors:  Ami B Shah; Katarzyna A Rejniak; Jana L Gevertz
Journal:  Math Biosci Eng       Date:  2016-12-01       Impact factor: 2.080

4.  Investigations of AGEs' inhibitory and nephroprotective potential of ursolic acid towards reduction of diabetic complications.

Authors:  Kishor Mazumder; Biswajit Biswas; Abdullah Al Mamun; Hasan Billah; Ahsan Abid; Kishore Kumar Sarkar; Bisti Saha; Shorrowar Azom; Philip G Kerr
Journal:  J Nat Med       Date:  2022-01-15       Impact factor: 2.343

5.  Inhibiting amyloid β-protein assembly: Size-activity relationships among grape seed-derived polyphenols.

Authors:  Eric Y Hayden; Ghiam Yamin; Shiela Beroukhim; Benson Chen; Mikhail Kibalchenko; Lin Jiang; Lap Ho; Jun Wang; Giulio M Pasinetti; David B Teplow
Journal:  J Neurochem       Date:  2015-09-02       Impact factor: 5.372

6.  Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.

Authors:  Emanuele Perrone; Paola Manara; Salvatore Lopez; Stefania Bellone; Elena Bonazzoli; Aranzazu Manzano; Luca Zammataro; Anna Bianchi; Burak Zeybek; Natalia Buza; Joan Tymon-Rosario; Gary Altwerger; Chanhee Han; Gulden Menderes; Gloria S Huang; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Pei Hui; Peter E Schwartz; Giovanni Scambia; Alessandro D Santin
Journal:  Mol Oncol       Date:  2020-01-14       Impact factor: 6.603

7.  A mass spectrometry-based assay for improved quantitative measurements of efflux pump inhibition.

Authors:  Adam R Brown; Keivan A Ettefagh; Daniel Todd; Patrick S Cole; Joseph M Egan; Daniel H Foil; Tyler N Graf; Bryan D Schindler; Glenn W Kaatz; Nadja B Cech
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

8.  Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.

Authors:  M Feng; J Q Jin; L Xia; T Xiao; S Mei; X Wang; X Huang; J Chen; M Liu; C Chen; S Rafi; A X Zhu; Y-X Feng; D Zhu
Journal:  Sci Adv       Date:  2019-05-08       Impact factor: 14.136

9.  IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.

Authors:  Yipeng Xu; Gabriela Pachnikova; He Wang; Yaoyao Wu; Dorothea Przybilla; Reinhold Schäfer; Zihao Chen; Shaoxing Zhu; Ulrich Keilholz
Journal:  Bosn J Basic Med Sci       Date:  2022-07-29       Impact factor: 3.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.